Practical non-Poissonian light source for passive decoy state quantum key distribution.

Passive decoy state quantum key distribution (QKD) has enormous potential in high-speed applications. In this Letter, an intrinsic-stable non-Poissonian light source was implemented with Faraday mirrors and could be a crucial element in realizing passive decoy state QKD. The stable g((2))(0) was obtained through a Hanbury Brown-Twiss experiment, and the results fit well with the theoretical value according to Curty et al.'s theory [Opt. Lett.34, 3238 (2009)].

Field test of wavelength-saving quantum key distribution network.

We propose a wavelength-saving topology of a quantum key distribution (QKD) network based on passive optical elements, and we report on the field test of this network on commercial telecom optical fiber at the frequency of 20 MHz. In this network, five nodes are supported with two wavelengths, and every two nodes can share secure keys directly at the same time. We also characterized the insertion loss and cross talk effects on the point-to-point QKD system after introducing this QKD network.

[Effectiveness of ezetimibe in improving lipid goal attainment in patients with coronary heart diseases treated with statin].

OBJECTIVE: To investigate the efficacy and safety of ezetimibe on uncontrolled LDL-C when added to ongoing statin therapy in patients with coronary heart diseases (CHD) and diabetes mellitus (DM). METHODS: 61 patients with LDL-C level exceeding target goal (<2.07 mmol/L) after 12 weeks' treatment with statins, received ezetimibe in addition to their ongoing statin therapy for 8 weeks. Lipid parameters, alanine aminotransferase (ALT), aspartic aminotransferase (AST) and creatine kinase (CK) were compared before and after the adding of ezetimibe. RESULTS: LDL-C before and after the adding of ezetimibe was (2.74+/-0.43) mmol/L and (2.19+/-0.32) mmol/L, respectively (P=0.03) in 61 patients. Ezetimibe added to statin therapy significantly reduced the LDL-C level and TC level by additional 20.1% and 19.1%, respectively (P<0.05). 74% (45/61) patients treated with ezetimibe added to statin reached their target LDL-C goal. No change of TG and HDL-C was observed and no change of AST, ALT and CK was found either. CONCLUSION: Ezetimibe added to statin therapy lowered LDL-C level further and improved the goal attainment in patients with CHD and DM.

[Correlativity between the polymorphisms of aldosterone synthase gene, Hind III restriction site on Y chromosome and essential hypertension].

OBJECTIVE: To investigate the relationship of associating the polymorphisms of CYP11B2 -344C/T and Hind III restriction site on Y chromosome with essential hypertension. METHODS: This study enrolled 654 patients with essential hypertension and 386 healthy subjects as control group. The genomic DNA was extracted from blood leukocytes. The DNA segments of CYP11B2 and Y chromosome were amplified from genomic DNA by polymerase chain reaction (PCR). The PCR products were digested with Hae III or Hind III at 37 degrees centigrade respectively. The digested products were subjected to agarose gel electrophoresis and stain with ethidium bromide. RESULTS: (1)The Hind III (-) genotype was found at 42.0% for patients with essential hypertension and 32.9% for control. The Hind III (-) genotype frequency of hypertension patient was significantly higher than that of the control (P was 0.03). The Hind III (+) genotype had a lower SBP and DBP than the Hind III (-) genotype (P was 0.01, P was 0.03). (2)With combining CC or CT genotype with Hind III (-) genotype, the relative risk suffering from hypertension was 1.998 fold high (P was 0.01). CONCLUSION: The polymorphism of Hind III restriction site on Y chromosome is associated with essential hypertension, and when combined with polymorphism of CYP11B2 -344C/T, may have a united role to increase the risk of suffering from hypertension disease.